<DOC>
	<DOCNO>NCT01590732</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose romidepsin give combination ifosfamide , carboplatin , etoposide ( ICE ) patient PTCL . The safety drug combination also study . Romidepsin design stop growth cancer cell block new blood vessel form around cancer cell . This may cause cancer cell die . Ifosfamide etoposide design slow stop growth cancer cell . Carboplatin design interfere growth cancer cell stop cell division , may cause cell die .</brief_summary>
	<brief_title>Phase I Study Romidepsin Plus ICE Patients With Relapsed Refractory Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign dose level romidepsin base join study . Up 4 dose level romidepsin test . Between 3-10 participant enrol dose level . The first group participant receive low dose level . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose romidepsin find . All participant receive dose level ifosfamide , carboplatin , etoposide . Study Drug Administration : Each Cycle 14 day . On Day 1 : - You receive romidepsin vein 4 hour . - You receive ifosfamide vein 24 hour . - You receive mesna vein 24 hour . This infusion begin 12 hour end ifosfamide infusion . Mesna give help reduce risk bladder-related side effect . - You receive carboplatin vein 1 hour . - You receive etoposide vein 2 hour . On Days 2-3 , receive etoposide vein 2 hour . On Day 4 , receive romidepsin vein 4 hour . If need , receive magnesium potassium replacement . Study Visits : On Day 1 every cycle : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . - You ECG . - You ask side effect may . Every week , blood ( 2 tablespoon ) draw routine test . Between Days 7-14 Cycles 2 , 4 , 6 , may CT PET/CT check status disease . Length Study Drug Administration : You may receive 6 cycle . You longer able take study drug combination disease get bad , intolerable side effect occur , unable follow study direction . Your participation study complete end-of-study visit . End-of-Study Visit : About 14 day last dose study drug : - You physical exam . - Blood ( 2 tablespoon ) draw routine test . - You may CT PET/CT check status disease . - You may bone marrow biopsy/aspirate check status disease . - You ECG . - You ask side effect may . This investigational study . Romidepsin FDA approve commercially available treatment cutaneous T-cell lymphoma ( CTCL ) patient receive least 1 prior systemic therapy . ICE FDA approve commercially available treatment several type lymphoma , include relapsed refractory Hodgkin 's lymphoma . The combination romidepsin ICE treatment PTCL investigational . Up 30 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Relapsed refractory TCL status include diagnosis peripheral TCLNOS , angioimmunoblastic TCL , anaplastic large cell lymphoma , hepatosplenic TCL , enteropathyassociated TCL , mycosis fungoides ( MF ) /cutaneous TCL transformation systemic TCL . 2 . Patients must receive least one chemotherapy regimen contain doxorubicin . 3 . At least one 1.5 cm bidimensional measurable lesion bone marrow positivity TCL . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 5 . Lab criterion absolute neutrophil count ( ANC ) &gt; /= 1000 cells/mm3 , platelet &gt; /= 80,000 cells/mm3 baseline bone marrow negative TCL involvement platelet &gt; /= 20,000 cells/mm3 baseline bone marrow positive TCL involvement , bilirubin &lt; /= 2 x upper limit normal ( ULN ) ( Gilbert 's &lt; /= 3 x ULN ) , creatinine &lt; /= 1.5 x ULN , ALT AST &lt; /= 3 x ULN . 6 . Negative pregnancy test female childbearing potential within 7 day prior start treatment . Patients reproductive potential must follow accept birth control method include hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence treatment 3 month completion treatment . 7 . Age &gt; /= 18 year . 8 . Voluntarily sign Institutional Review Board ( IRB ) approve informed consent document ( ICD ) performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 1 . History another malignancy remission least 2 yr ( except nonmelanoma skin cancer , stage 0 melanoma , localized prostate cancer , cervical cancer situ ) 2 . Known active Central Nervous System ( CNS ) lymphoma . 3 . Ejection fraction ( EF ) &lt; 40 % , myocardial infarction ( MI ) within past 3 month , uncontrolled angina , severe uncontrolled ventricular arrythmias , ECG evidence acute ischemia . 4 . Grade 3 infection within 2 week first dose romidepsin plus ICE . 5 . Pregnant lactating . 6 . Receipt another investigational drug within 14 day enrollment . 7 . Patients previous hypersensitivity reaction study drug component ( ex : podophyllum povidone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Peripheral T-Cell Lymphoma</keyword>
	<keyword>PTCL</keyword>
	<keyword>Relapsed refractory T-Cell Lymphoma</keyword>
	<keyword>TCL</keyword>
	<keyword>Peripheral TCL-NOS</keyword>
	<keyword>Angioimmunoblastic TCL</keyword>
	<keyword>Anaplastic large cell lymphoma</keyword>
	<keyword>Hepatosplenic TCL</keyword>
	<keyword>Enteropathy-associated TCL</keyword>
	<keyword>Romidepsin</keyword>
	<keyword>Istodax</keyword>
	<keyword>Depsipeptide</keyword>
	<keyword>FK228</keyword>
	<keyword>Etoposide</keyword>
	<keyword>VePesid</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
</DOC>